Clinical efficacy of traditional chinese medicine on acute myocardial infarction—A prospective cohort study

Wen-hui Duan; Fang Lu; Li-zhi Li; Cheng-long Wang; Jian-gang Liu; Qiao-ning Yang; Feng Gu; Lei Zhang; Da-zhuo Shi

doi:10.1007/s11655-012-1116-9

Your Location：

Home >

Browse articles >

Clinical efficacy of traditional chinese medicine on acute myocardial infarction—A prospective cohort study

Updated：2021-08-27

- Clinical efficacy of traditional chinese medicine on acute myocardial infarction—A prospective cohort study
- Chinese Journal of Integrative Medicine Vol. 18, Issue 11, Pages: 807-812(2012)
- Affiliations：
  
  Cardiovascular Diseases Center, Xiyuan Hospital, China Academy of Chinese Medical Sciences,Beijing,China
- Author bio：
- Funds：
  
  Supported by Grants from National Eleventh Five-Year Key Programs for Science and Technology Development of China (No. 2006BAI04A01-2) and the Second Group Dominant Disease of China Academy of Chinese Medical Sciences (No. CACMS07Y001)
- DOI：10.1007/s11655-012-1116-9
  CLC：
- Published：2012，
  
  Published Online：16 August 2012，
Scan for full text
Duan, Wh., Lu, F., Li, Lz. et al. Clinical efficacy of traditional chinese medicine on acute myocardial infarction—A prospective cohort study., Chin. J. Integr. Med. 18, 807–812 (2012). https://doi.org/10.1007/s11655-012-1116-9

Wen-hui Duan, Fang Lu, Li-zhi Li, et al. Clinical efficacy of traditional chinese medicine on acute myocardial infarction—A prospective cohort study. [J]. Chinese Journal of Integrative Medicine 18(11):807-812(2012)
Duan, Wh., Lu, F., Li, Lz. et al. Clinical efficacy of traditional chinese medicine on acute myocardial infarction—A prospective cohort study., Chin. J. Integr. Med. 18, 807–812 (2012). https://doi.org/10.1007/s11655-012-1116-9 DOI：

Wen-hui Duan, Fang Lu, Li-zhi Li, et al. Clinical efficacy of traditional chinese medicine on acute myocardial infarction—A prospective cohort study. [J]. Chinese Journal of Integrative Medicine 18(11):807-812(2012) DOI： 10.1007/s11655-012-1116-9.

摘要

To evaluate the clinical effects of Chinese medicine (CM) on acute myocardial infarction (AMI) with a prospective cohort study. A total of 334 AMI patients from January 2007 to March 2009 were consecutively enrolled

and were assigned to a treatment group (169 cases) treated with combined therapy (CM for at least one month and Western medicine) and a control group (165 cases) with Western medicine alone. Clinical data including age

gender

smoking

medical history

infarction area

heart functional classification

CM syndrome scores

blood-stasis syndrome score

primary end-point (death

nonfatal myocardial infarction

and revascularization) and secondary end-point (ischemic stroke

rehospitalization due to angina

heart failure and shock)

were collected. CM syndrome scores

blood-stasis syndrome score

primary end-point and secondary end-point were collected during the 6-month follow-up. Kaplan-Meier method was used for the survival analysis. The multifactor analysis was analyzed by Cox proportional hazards regression. At the end of 6-month the CM syndrome score and bloodstasis syndrome score in the treatment group were lower than those in the control group (P<0.01)

especially the symptoms of chest pain

spontaneous perspiration and insomnia. Rehospitalization rate due to angina during the 6-month follow-up in the treatment group (2.96%) was lower than that in the control group (7.88%

P<0.05). Kaplan- Meier survival curve showed that event-free cumulated survival of rehospitalization due to angina during the 6-month follow-up in the treatment group was higher than that in the control group (Log rank 4.700

P=0.03). Cox regression analysis showed that heart dysfunction [hazard ratio (HR)=1.601

95% CI=1.084–2.364

P=0.018] and diabetes mellitus (HR=1.755

95% CI=1.031–2.989

P=0.038) were hazard factors to end-point

whereas CM (HR 0.405

95% CI=0.231–0.712

P=0.002)

percutaneous coronary intervention (PCI

HR=0.352

95% CI=0.204–0.607

P<0.001) and angiotensin converting enzyme (ACE) inhibitors (HR=0.541

95% CI=0.313–0.936

P=0.028) were protective factors. CM therapy could decrease CM syndrome scores and blood-stasis syndrome score

reduce the rehospitalization rate during 6-month follow-up due to angina. Heart dysfunction and diabetes mellitus were hazard factors to end-point

whereas CM

PCI and ACE inhibitors were protective factors.

Abstract

gender

smoking

medical history

infarction area

heart functional classification

CM syndrome scores

blood-stasis syndrome score

primary end-point (death

nonfatal myocardial infarction

and revascularization) and secondary end-point (ischemic stroke

rehospitalization due to angina

heart failure and shock)

were collected. CM syndrome scores

blood-stasis syndrome score

especially the symptoms of chest pain

spontaneous perspiration and insomnia. Rehospitalization rate due to angina during the 6-month follow-up in the treatment group (2.96%) was lower than that in the control group (7.88%

P=0.03). Cox regression analysis showed that heart dysfunction [hazard ratio (HR)=1.601

95% CI=1.084–2.364

P=0.018] and diabetes mellitus (HR=1.755

95% CI=1.031–2.989

P=0.038) were hazard factors to end-point

whereas CM (HR 0.405

95% CI=0.231–0.712

P=0.002)

percutaneous coronary intervention (PCI

HR=0.352

95% CI=0.204–0.607

P<0.001) and angiotensin converting enzyme (ACE) inhibitors (HR=0.541

95% CI=0.313–0.936

P=0.028) were protective factors. CM therapy could decrease CM syndrome scores and blood-stasis syndrome score

reduce the rehospitalization rate during 6-month follow-up due to angina. Heart dysfunction and diabetes mellitus were hazard factors to end-point

whereas CM

PCI and ACE inhibitors were protective factors.

关键词

acute myocardial infarctionChinese Medicinesurvival analysiscohort study

Keywords

acute myocardial infarctionChinese Medicinesurvival analysiscohort study

references

Spaulding C, Henry P, Teiger E, Beatt K, Bramucci E, Carrié D, et al. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med 2006;355:1093–1104.

Xiyuan Hospital. The “Anti-infarct Mixture” for acute myocardial infarction—clinical analysis of 118 cases. Chin J Intern Med (Chin) 1976;1:212–215.

Yin HJ, Wang XG, Shi DZ. Effects of GSTT on release of TNF-α and IL-1β in rats with myocardial ischemia reperfusion injury. Med J Chin PLA (Chin) 2006;31:986–987.

Shang LZ, Wei DW, Wang F. Effects of ligustrazine on expression of HSP25 and p38MAPK proteins in rats with myocardial ischemia reperfusion injury. China J Tradit Chin Med Pharm (Chin) 2008;23:882–884.

Li YQ, Jin M, Qiu SL, Zhu TG, Bian H, Wang CL, et al. Effects of Chinese herbal medicine for benefiting qi and nourishing yin to promote blood circulation on ventricular wall motion of AMI patients after revascularization. Chin J Integr Tradit West Med (Chin) 2009;29:300–304.

Lu XY, Shi DZ, Xu H, Chen KJ, Lu SZ, et al. Clinical study on effect of Xiongshao Capsule on restenosis after percutaneous coronary intervention. Chin J Integr Tradit West Med (Chin) 2006;26:13–16.

Chinese Society of Cardiology of Chinese Medical Association, Editorial Board of Chinese Journal of Cardiology. Guide to diagnosis and treatment of acute myocardial infarction in China. Chin J Cardiol (Chin) 2001;29:710–725.

Cardiovascular Institute of Traditional Chinese Medicine Professional Committee. Diagnostic criteria for coronary heart disease. Chin J Integr Tradit West Med (Chin) 1991;11:257–260.

National Standards for Chinese medicine Industry of People’s Republic of China, Chinese medicine Syndrome. Clinic terminology of traditional Chinese medical diagnosis and treatment—Syndromes (GB/T l6751. 2-1997).

Professional Committee of Blood Circulation Research, Chinese Association of Integrative Medicine. Diagnosis standard of blood stasis synrome. Chin J Integr Tradit West Med (Chin) 1987;7:129–131.

Wang J. Study on diagnostic criteria of blood stasis syndrome. Research and clinical application of promoting blood circulation and removing blood stasis. Beijing: Beijing Medical University and Peking Union Medical College Press; 1993:7.

Qiu SL, Jin M, Zhu TG, Quan X, Liang Y, Shi DZ, et al. Effect of replenishing qi and nourishing yin to promote the blood circulation on 103 patients with acute myocardial infarction after reperfusion. J Capit Med Univ (Chin) 2009;30:426–429.

Chen KJ, Shi DZ, Xu H, Lu SZ, Li TC, Ke YN, et al. XS0601 reduces the incidence of restenosis: a prospective study of 335 patients undergoing percutaneous coronary intervention in China. Chin Med J 2006;119:6–13.

Duan WH, Li LZ, Wang CL, Gao ZY, Shi DZ, et al. Study on correlation between heart function and Chinese medicine syndrome distribution of acute myocardial infarction. Beijing J Tradit Chin Med (Chin) 2010;29:4–6.

Lin Q, Nong YB, Duan WH. Retrospective study on influence of Chinese herbal drugs on long-term prognosis of acute myocardial infarction. J Beijing Univ Tradit Chin Med (Chin) 2006;29:419–421.

Ryo K, Nobuhisa H, Hiroshi K, Yukio Tsurumi, Hiroshi Ogawa, et al. Primary percutaneous coronary intervention vs conservative treatment for acute ST elevation myocardial infarction: short- and long-term follow-up according to disease severity. Circ J 2008;72:1391–1396.

FULL TEXT LINK

More>

Views

126

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

Combined therapy with Chinese medicine and percutaneous transradial coronary intervention for a centenarian patient with acute myocardial infarction

Huoxue Anxin Recipe (活血安心方) promotes myocardium angiogenesis of acute myocardial infarction rats by up-regulating miR-210 and vascular endothelial growth factor

Future view and development of immunology: Exploring the immunology based on Chinese medicine and culture

Cost-effectiveness analysis of combined Chinese medicine and Western medicine for ischemic stroke patients

Objective tongue inspection on 142 liver cancer patients with damp-heat syndrome

Related Author

No data

Related Institution

Heart Center, Guangdong Provincial Hospital of Chinese Medicine

Department of Cardiovascular, Guang’anmen Hospital, China Academy of Chinese Medical Sciences

Department of Shang Han Teaching and Research, Hubei University of Traditional Chinese Medicine

Department of Immunology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences

Department of Molecular Biology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰